Analyst Price Target is $12.75
▲ +706.96% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Century Therapeutics in the last 3 months. The average price target is $12.75, with a high forecast of $24.00 and a low forecast of $6.00. The average price target represents a 706.96% upside from the last price of $1.58.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Century Therapeutics. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Read More
